Hengrui's Deal With Bristol Myers Squibb Should Ease Concerns Over Dealmaking Slowdown -- Market Talk

Dow Jones05-12 15:12

0712 GMT - The strategic partnership and licensing deals between Hengrui Pharmaceuticals and BRistol Myers Squibb should help ease investor concerns over any slowdown in Hengrui's dealmaking activity, Nomura China healthcare analyst Jialin Zhang says in a note. Zhang adds that seven months have passed since Hengrui last announced a collaboration agreement, a gap that explains the recent weakness in its share price. However, the BMS deal reaffirms its capabilities and serves as a proxy for China's biopharma innovation out-licensing, he says. "We also believe the company set a good example regarding maintaining confidentiality about this deal until it was officially disclosed," he adds. Nomura maintains a buy rating and a target price of HK$87.49 on Hengrui's Hong Kong-listed stock. The H-shares are last at HK$68.80. (jason.chau@wsj.com)

(END) Dow Jones Newswires

May 12, 2026 03:12 ET (07:12 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2634429864?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 15:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634429864","market":"hk","top_or_hot":-1,"title":"Hengrui's Deal With Bristol Myers Squibb Should Ease Concerns Over Dealmaking Slowdown -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0712 GMT - The strategic partnership and licensing deals between Hengrui Pharmaceuticals and BRistol Myers Squibb should help ease investor concerns over any slowdown in Hengrui's dealmaking activity, Nomura China healthcare analyst Jialin Zhang says in a note. Zhang adds that seven months have passed since Hengrui last announced a collaboration agreement, a gap that explains the recent weakness in its share price. However, the BMS deal reaffirms its capabilities and serves as a proxy for China's biopharma innovation out-licensing, he says. \"We also believe the company set a good example regarding maintaining confidentiality about this deal until it was officially disclosed,\" he adds. Nomura maintains a buy rating and a target price of HK$87.49 on Hengrui's Hong Kong-listed stock. The H-shares are last at HK$68.80. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 12, 2026 03:12 ET (07:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hengrui's Deal With Bristol Myers Squibb Should Ease Concerns Over Dealmaking Slowdown -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHengrui's Deal With Bristol Myers Squibb Should Ease Concerns Over Dealmaking Slowdown -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-12 15:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0712 GMT - The strategic partnership and licensing deals between Hengrui Pharmaceuticals and BRistol Myers Squibb should help ease investor concerns over any slowdown in Hengrui's dealmaking activity, Nomura China healthcare analyst Jialin Zhang says in a note. Zhang adds that seven months have passed since Hengrui last announced a collaboration agreement, a gap that explains the recent weakness in its share price. However, the BMS deal reaffirms its capabilities and serves as a proxy for China's biopharma innovation out-licensing, he says. \"We also believe the company set a good example regarding maintaining confidentiality about this deal until it was officially disclosed,\" he adds. Nomura maintains a buy rating and a target price of HK$87.49 on Hengrui's Hong Kong-listed stock. The H-shares are last at HK$68.80. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 12, 2026 03:12 ET (07:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFTCPJ56.SGD","symbol_name":"Janus Henderson Global Life Sciences A Acc SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634429864","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634429864","pubTimestamp":1778569920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0712 GMT - The strategic partnership and licensing deals between Hengrui Pharmaceuticals and BRistol Myers Squibb should help ease investor concerns over any slowdown in Hengrui's dealmaking activity, Nomura China healthcare analyst Jialin Zhang says in a note. Zhang adds that seven months have passed since Hengrui last announced a collaboration agreement, a gap that explains the recent weakness in its share price. However, the BMS deal reaffirms its capabilities and serves as a proxy for China's biopharma innovation out-licensing, he says. \"We also believe the company set a good example regarding maintaining confidentiality about this deal until it was officially disclosed,\" he adds. Nomura maintains a buy rating and a target price of HK$87.49 on Hengrui's Hong Kong-listed stock. The H-shares are last at HK$68.80. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","BK0239":"医药制造","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK4588":"碎股","BK0188":"融资融券","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","BK0012":"证金概念","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","BK0028":"国家队","BK4007":"制药","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","BK4581":"高盛持仓","BK0060":"抗癌","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BMY":"施贵宝","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC"},"translate_title":"恒瑞与百时美施贵宝的交易应该会缓解人们对交易放缓的担忧——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9,"BMY":1.5},"content_text":"0712 GMT - The strategic partnership and licensing deals between Hengrui Pharmaceuticals and BRistol Myers Squibb should help ease investor concerns over any slowdown in Hengrui's dealmaking activity, Nomura China healthcare analyst Jialin Zhang says in a note. Zhang adds that seven months have passed since Hengrui last announced a collaboration agreement, a gap that explains the recent weakness in its share price. However, the BMS deal reaffirms its capabilities and serves as a proxy for China's biopharma innovation out-licensing, he says. \"We also believe the company set a good example regarding maintaining confidentiality about this deal until it was officially disclosed,\" he adds. Nomura maintains a buy rating and a target price of HK$87.49 on Hengrui's Hong Kong-listed stock. The H-shares are last at HK$68.80. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 03:12 ET (07:12 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2634429864","isCrawlerRequest":true}